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ABSTRACT 
Objective: Bosentan is an endothelin receptor antagonist (ERA) indicated for the treatment of Pulmonary arterial hypertension (PAH). The aim of 
the present study involves the development of sustained release matrix tablets of bosentan in order to release the drug in sustained and predictable 
manner. 
Methods: Bosentan SR Matrix tablets were prepared by Wet granulation method. The tablets were evaluated for Hardness, Thickness, Friability and 
Drug content and were subjected to a 12 hours in vitro drug release studies. 
Results: The amount of Bosentan released from the tablet formulations at different time intervals was estimated using a UV Spectroscopy method. 
Among all the formulations are prepared by using different polymers like HPMC K 4 M, HPMC K15 M at different ratios.  
Conclusion: We Can Conclude that Among the Ten formulations, F-2 formulation containing drug to HPMC K 4 M in ratio 1:0.5 is optimized based 
on its ability to sustain drug release till 12 hours of dissolution study, The results of the study clearly demonstrated that HPMC matrix tablet 
formulation is an effective and promising drug delivery system for once daily administration of Bosentan. 
Keywords: Bosentan monohydrate, Wet granulation method, Sustained Release Matrix, Hydroxy Propyl methyl Cellulose (HPMC). 
 
INTRODUCTION 
The oral route of administration has been used the most for both 
conventional and novel drug delivery systems. There are many 
obvious reasons for this, not the least of which would include 
acceptance by the patient and ease of administration. The types of 
sustained and controlled release systems employed for oral 
administration include virtually every currently known theoretical 
mechanism for such application. This is because there is more 
flexibility in dosage design, since constraints, such as sterility and 
potential damage at the site of administration, are minimized [1]. 
Sustained release dosage forms may be defined as any drug or 
dosage form modification that prolonged but not necessarily 
uniform release of drug. The goal of a sustained release dosage form 
is to maintain therapeutic blood or tissue levels of the drug for an 
extended period. This is usually accomplished by attempting to 
obtain zero-order release from the dosage form. Zero-order release 
constitutes the drug release from the dosage form that is 
independent of the amount of drug in the delivery system (i. e., 
constant release rate). Sustained release systems generally do not 
attain this type of release and usually try to mimic zero-order 
release by providing drug in a slow first-order fashion (i. e., 
concentration dependent). Systems that are designated as prolonged 
release can also be considered as attempts at achieving sustained 
release delivery [1, 3]. 
Over the past 30 years, as the expense and complications involved in 
marketing new drug entities have increased, with concomitant 
recognition of the therapeutic advantages of controlled drug 
delivery, the goal in the designing sustained –or controlled delivery 
system is to reduce the frequency of dosing or to increase 
effectiveness of the drug by localization at the site of action, 
reducing the dose required, or providing uniform drug delivery [2]. 
Bosentan is a endothelin receptor antagonist used in the treatment 
of pulmonary artery hypertension (PAH). It is readily absorbed from 
the gastrointestinal tract with oral bioavailability of about 50% and 
a plasma elimination half-life is 5 hours. Administration of Bosentan 
in a sustained release dosage form would be more desirable by 
maintaining the plasma concentrations of the drug well above the 
therapeutic concentration. 
MATERIALS AND METHODS 
Materials 
Bosentan was provided by MSN Laboratories Pvt. Ltd, Hyderabad, 
HPMC grades were procured from Yarrow Chem. Products, Mumbai, 
PVP- K 30, Talc, Magnesium stearate, and MCC was bought from 
Signet Chem., Mumbai. 
Methodology 
Preformulation Studies  
Standardization of Bosentan by UV-Visible Spectrophotometry 
in 0.1 N Hcl Solutions  
Preparation of stock solution 
Stock solution 100µg/ml of Bosentan was prepared in 0.1N Hcl 
solution. This solution was approximately diluted with 0.1N Hcl to 
obtain a concentration of 10µg/ml. The resultant solution was 
scanned in the range of 200- 400 nm using UV double beam 
spectrophotometer (Lab India UV-3000+). 
Standard calibration of Bosentan in 0.1N Hcl 
100mg of Bosentan was accurately weighed and dissolved in100 ml 
of 0.1N Hcl to obtain a concentration of 1000µg/ml. From the above 
10 ml was withdrawn and diluted to 100 ml to obtain a 
concentration of 100µg/ml. From this stock solution aliquots of 0.5 ml, 
1 ml, 1.5 ml, 2 ml and 2.5 ml were diluted in 10 ml volumetric flask 
with phosphate buffer to give concentrations in range of 10µg/ml to 
70µg/ml respectively, absorbance was measured at 242 nm. 
Standardization of Bosentan by UV-Visible Spectrophotometry 
in pH 
Preparation of stock solution  
6.8 Solutions  
Stock solution 100µg/ml of Bosentan was prepared in phosphate 
buffer of pH 6.8. This solution was approximately diluted with 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491               Vol 6, Issue 11, 2014 
Innovare 
Academic Sciences 
Ganesh et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 11, 111-118 
 
112 
phosphate buffer of pH 6.8 to obtain a concentration of 10µg/ml. 
The resultant solution was scanned in range of 200- 400 nm using 
UV double beam spectrophotometer (Lab India UV-3000+). 
Standard calibration of Bosentan in phosphate buffer of pH
Carr’s compressibility index 
 6.8 
100mg of Bosentan was accurately weighed and dissolved in 100 ml of 
pH 6.8 phosphate buffer to obtain a concentration of 1000µg/ml. From 
the above 10 ml was withdrawn and diluted to 100 ml to obtain a 
concentration of 100µg/ml.  
From this stock solution aliquots of 0.5 ml, 1 ml, 1.5 ml, 2 ml and 2.5 ml 
were diluted in 10 ml volumetric flask with phosphate buffer to give 
concentrations in range of 5µg/ml to 20µg/ml respectively, 
absorbance was measured at 243 nm. 
Drug- Excipient Compatibility by FTIR studies  
In the preparation of Sustained release tablet, drug and polymer 
may interact as they are in close contact with each other, which 
could lead to instability of the drug. Preformulation studies 
regarding drug-polymer interactions are therefore very critical in 
selecting appropriate polymers.  
FT-IR spectroscopy (Agilent) was employed to ascertain the 
compatibility between bosentan and selected polymers. The 
individual drug and drug with excipients were scanned separately. 
Procedure 
Potassium bromide was mixed with drug and polymer in the ratio of 
100:1 and pellet was prepared using KBr pellet press and spectrum 
was taken using FTIR (Agilent). FT-IR spectrum of bosentan was 
compared with spectrum of bosentan and polymer. Disappearance of 
bosentan peaks or shifting of peak in any of the spectra was studied. 
Angle of repose 
The angle of repose of blends was determined by the funnel method. 
The accurately weighed blend was taken in funnel. The height of the 
funnel was adjusted in such a way that the tip of the funnel just 
touched the apex of the heap of the blend. The blend was allowed to 
flow from the funnel on the surface. The diameter and height of the 
heap formed from the blend were measured. The angle of repose 
was calculated using following formula [3]. 
Tan Ѳ= h/r 
Where, “h” is height of the heap and “r” is the radius of the heap of 
granules. 
The Carr’s compressibility Index was calculated from Bulk density and 
tapped density of the blend. A quantity of 2g of blend from each 
formulation, filled into a 10 mL of measuring cylinder. Initial bulk 
volume was measured, and cylinder was allowed to tap from the 
height of 2.5 cm. The tapped frequency was 25±2 per min to measure 
the tapped volume of the blend. The bulk density and tapped density 
were calculated by using the bulk volume and tapped volume. Carr’s 
compressibility index was calculated by using following formula. 
Carr’s compressibility index (%) = [(Tapped density-Bulk 
density) X100]/Tapped density 
Bulk Density (BD)  
An accurately weighed powder blend from each formula was lightly 
shaken to break any agglomerates formed and it was introduced in 
to a measuring cylinder. The volume occupied by the powder was 
measured which gave bulk volume. The bulk densities (BD) of 
powder blends were determined using the following formula. 
Bulk density = Total weight of powder / Total volume of 
powder 
Tapped bulk density (TBD)  
An accurately weighed powder blend from each formula was lightly 
shaken to break any agglomerates formed and it was introduced into 
a measuring cylinder. The measuring cylinder was tapped until no 
further change in volume was noted which gave the tapped volume. 
The tapped bulk densities (TBD) of powder blends were determined 
using the following formula. [4]. 
TBD= Total weight of powder / Total volume of tapped powder 
Preparation of tablets  
Wet granulation method 
All the powders were passed through 80 mesh. Required quantities 
of all ingredients were mixed thoroughly and a sufficient volume of 
granulating agent was added slowly. After enough cohesiveness was 
obtained, the mass was sieved through 22/44 mesh. The granules 
were dried at 40 C for 12 hrs. Once, dry the granules retained on 44 
mesh were mixed with 10% of fine granules that passed through 44 
mesh. Talc and magnesium stearate were added as glidant and 
lubricant. In all formulations, the amount of the active ingredient is 
equivalent to 62.5 mg of Bosentan (Table 1). 
 
Table 1: Formulations Containing HPMC K 4 M, HPMC K 15 M (Wet granulation) 
S. No. Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
1 Bosentan 62.5 62.5 62.5 62.5 62.5 62.5 62.5 62.5 62.5 62.5 
2 HPMC K 4 M 15.62 31.25 62.5 93.75 125 --- --- --- --- --- 
3 HPMC K 15 M --- --- --- --- --- 15.62 31.25 62.5 93.75 125 
4 PVP-K 30 (5%) QS QS QS QS QS QS QS QS QS QS 
5 Talc 6 6 6 6 6 6 6 6 6 6 
6 Mg. Stearate 6 6 6 6 6 6 6 6 6 6 
7 MCC 209.8 194.25 163 131.75 100.5 209.8 194.25 163 131.75 100.5 
 Total Weight 300 300 300 300 300 300 300 300 300 300 
 
Evaluation of tablets 
The weight of tablets was evaluated on 20 tablets using an electronic 
balance. Friability was determined using 6 tablets in Roche friability 
tester at 25rpm. Hardness of the tablets was evaluated using a 
Monsanto hardness tester. The hardness of all the formulation was 
between 4-5 kg/cm2
In vitro dissolution studies 
. 
In vitro drug release studies from the prepared matrix tablets were 
conducted using USP type II apparatus at 370C ±0.50
Dependent-model method (Data analysis) 
C at 50rpm. 
Dissolution mediums used were 900 mL of 0.1N HCl and phosphate 
buffer of pH 6.8. The release rates from SR matrix tablets were 
conducted in HCl solution (pH 1.2) for 2 hrs and changed to 
phosphate buffer (pH 6.8) for further time periods. The samples 
were withdrawn at desired time periods from dissolution media and 
the same were replaced with fresh dissolution media of respective 
pH. The samples were analyzed by UV-Visible Spectrophotometer 
(Lab India 3000+). The amounts of drug present in the samples were 
calculated with the help of appropriate calibration curves 
constructed from reference standards. Drug dissolved at specified 
time periods was plotted as percent release versus time curve [5,6].  
In order to describe the Bosentan release kinetics from individual 
tablet formulations, the corresponding dissolution data were fitted 
in various kinetic dissolution models: zero order, first order, 
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Higuchi, Korsmeyer Peppas. When these models are used and 
analyzed in the preparation, the rate constant obtained from these 
models is an apparent rate constant. The release of drugs from the 
matrix tablets can be analysed by release kinetic theories. To study 
the kinetics of drug release from matrix system, the release data 
were fitted into Zero order as the cumulative amount of drug release 
vs. time (Eqn.3), first order as log cumulative percentage of drug 
remaining vs. time (Eqn.4), Higuchi model as cumulative percent 
drug release vs. square root of time (Eqn.5). To describe the release 
behavior from the polymeric systems, data were fitted according to 
well known exponential Korsmeyer – Peppas equation as log 
cumulative percent drug release vs log of time equation (Eqn.6). 
(i) Zero order kinetics  
Qt=K0t……………………………Eqn.(3) 
Where, 
Q= Amount of drug release in time t 
K0 = Zero order rate constant expressed in unit of concentration 
/time, t = Release time 
(ii) First order kinetics 
Log Q=Log Q0-kt/2.303…………Eqn.(4) 
Where, Q0= is the initial concentration of drug 
k= is the first order rate constant 
t =release time 
(iii) Higuchi kinetics 
Q=kt1/2……………………………Eqn.(5) 
Where, k= Release rate constant 
t=release time, Hence the release rate is proportional to the 
reciprocal of the square root of time. 
(iv) Korsmeyer-Peppas 
First 60% in vitro release data were fitted in an equation of 
Korsmeyer et al. to determine the release behavior from controlled 
release polymer matrix system. The equation is also called as power 
law, 
Mt /M∞ =Kt n …………………… Eqn.(6) 
Where, 
Mt = amount of drug released at time t 
M∞ = amount of drug released after infinite time 
Mt /M∞ = fraction solute release 
t = release time 
K = kinetic constant incorporating structural and geometric 
characteristics of the polymer system 
n = diffusional exponent that characterizes the mechanism of the 
release of traces. The magnitude of the release exponent “n” 
indicates the release mechanism (i. e. Fickian diffusion, Non Fickian, 
supercase II release).  
For matrix tablets, values of n of near 0.5 indicates Fickian diffusion 
controlled drug release, and an n value of near 1.0 indicates erosion 
or relaxational control (case II relaxational release transport, non 
Fickian, zero order release). Values of n between 0.5 and 1 regarded 
as an indicator of both diffusion and erosion as overall release 
mechanism commonly called as anomalous release mechanism [7]. 
RESULTS AND DISCUSSION 
Preformulation characteristics  
The drug Bosentan was standardized by UV method in 0.1N Hcl and 
pH 6.8 Buffer separately. The lambda max were 242 nm and 243 nm 
in 0.1N Hcl and pH 6.8 buffer respectively and the linearity range 





 of Bosentan in 0.1 N HCl (242 nm) 
Table 2: Absorbences of Bosentan in 0.1N HCL 
S. No. Concentration(mcg/ml) Absorbance(nm) 
1 10 0.141 
2 20 0.207 
3 30 0.293 
4 40 0.390 
5 50 0.470 
6 60 0.547 
7 70 0.654 
 
 
Fig. 2: Calibration curve of Bosentan in 0.1N HCL 
 
Fig. 3: λmax of Bosentan in pH 6.8 Buffer (243 nm)
 
 
Table 3: Absorbences of Bosentan in 6.8 pH Phosphate buffer 
S. No. Concentration(mcg/ml) Absorbance (nm) 
1 5 0.356 
2 10 0.585 
3 12 0.683 
4 15 0.821 
5 18 0.997 
6 20 1.081 
 
 
Fig. 4: Calibration curve of Bosentan in 6.8 pH Phosphate buffer 
 
Drug Excipient Compatibility Studies- FTIR 
Drug-Excipient compatibility studies by FTIR revealed no 
interaction between drug and the polymers used in the formulation 
thus showing compatibility. 
 
 
Fig. 5: FTIR spectra of Bosentan pure Drug 
 
 
Fig. 6: FTIR spectra of Bosentan pure Drug + HPMC K 4 M 
 
 
Fig. 7: FTIR spectra of Optimized Formulation (Bosentan+HPMC 
K 4 M+PVP-K 30+Talc+Mg. Stearate+MCC) 
Differential Scanning Calorimetry (DSC): 
The compatibility and interactions between drugs and polymer were 
checked using differential scanning calorimetry (DSC). Any possible 
drug polymer interaction can be studied by thermal analysis.  
The DSC study was performed on pure drug (Bosentan) and 
Optimized Formulations (drug + HPMC K4M + pvp k 30 + talc + Mg. 
Stearate + Mcc). The study was carried out using Hitachi 6300.  
The 2 mg of sample were heated in a hermetically sealed aluminum 
pans in the temperature range of 30-220°c at heating rate of 10°c 
/min under nitrogen flow of 40 ml/min. Finally hence their no 
interaction was found between drug and the polymers. 
 
 




Fig. 9: Differential Scanning Calorimetry analysis of Optimized 
Formulation (Drug+HPMCK4M+PVP k 30+Talc+Mg. 
Stearate+Mcc) 
 
Physical characteristics of blends and tablets 
The blends of different formulations were evaluated for angle of 
repose, Carr’s compressibility index etc., The results of Angle of 
repose and Carr’s compressibility Index (%) ranged from 16-28 and 
14-16, respectively which showed that blends from all the 
formulations having good flow property. The hardness and 
percentage friability ranged from 3.5-5kg/cm2
In vitro dissolution studies 
 and 0.28-0.55% 
respectively. 
Bosentan monohydrate sustained release tablets were prepared by 
using HPMC polymers. The release profiles of Bosentan sustained 
release tablets were plotted as Fig.7-9. The release rate of Bosentan 
mainly controlled by the hydration and swelling properties of HPMC 
which forms a gel layer that controls the water penetration and drug 
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be clearly seen from the variation of the dissolution profiles.  Among 
all the formulations (F-1 to F-10) Contained Bosentan and HPMC 
K4M & HPMC K 15M Polymers in different ratios i. e., 
1:0.25,1:0.5,1:1,1:1.5 and 1:2, It was found that drug release of 
among all the formulations, F-2 containing HPMC K 4 M in ratio of 1: 
0.5 could retard drug for relatively 12 hrs compared to all other 
formulations. So Formulation (F-2) has showed maximum amount of 
drug released with drug release of 96.3 % in 12 hours, so it is chosen 
Optimized formulation. For matrix tablets, an ‘n’ value near to 0.5 
indicates diffusion control and an ‘n’ value near to 1 indicates 
relaxation or erosion control. The intermediate value suggests that 
diffusion and erosion contributes to overall release mechanism. A 
value of ‘n’ for all matrices studied here was ranged between 0.628 
to 0.894, indicating an anomalous behavior corresponding to 
swelling, diffusion and erosion mechanism.It was also observed that 
highest correlation was found for Zero order profile (R2
When the hydrophilic polymer tablets come in contact with the 
dissolution medium, they take up water and swell forming a viscous gel 
barrier. In case of hydrophilic matrix tablets, the initial swelling may aid 
dissolution of the freely soluble drugs, and the dissolved drug diffuses 
out of the swollen gel barrier into the dissolution medium. Unless the 
swollen gel barrier erodes, further seeping in of the dissolution medium 
does not occur. Thus, the release rate of the drug depends on the 
strength of the gel barrier i. e. the proportion of the hydrophilic polymer 
in the matrix tablet, its rate of hydration and viscosity. 
 > 0.934), 
which indicates the drug release via diffusion mechanism from 
hydrophilic matrices. 
Phenomenon of Drug Release Kinetics 
The optimized formulation F2 was subjected to graphical 
representation to assess the kinetics of drug release. The release of 
drug was observed to follow the Zero order release kinetics. The 
initial burs effect was observed as per Zero order kinetics. Hence the 
drug release was mainly found to be concentration dependent. 
Hence we conclude that diffusion is the mechanism of drug released. 
 
Table 4: Pre compression parameters 








Angle of repose (Ө) 
F1 0.519±0.025 0.562±0.47 1.17±0.17 14.16±0.65 23.°.47' 
F2 0.577±0.048 0.526±0.49 1.75±0.52 15.91±0.54 16°.68' 
F3 0.519±0.016 0.612±0.45 1.64±0.46 14.73±0.32 24°.13' 
F4 0.527±0.055 0.664±0.37 1.48±0.18 15.77±0.76 22°.07' 
F5 0.585±0.041 0.531±0.29 1.35±0.25 15.48±0.14 27°.98' 
F6 0.554±0.036 0.556±0.74 1.46±0.47 14.35±0.45 24°.55' 
F7 0.522±0.086 0.512±0.92 1.57±0.65 15.57±0.36 23°.67' 
F8 0.562±0.099 0.542±0.19 1.59±0.87 14.94±0.29 26°.35' 
F9 0.543±0.067 0.556±0.84 1.45±0.57 16.01±0.66 28°.46' 
F10 0.511±0.026 0.547±0.97 1.41±0.45 14.65±0.43 21°.17' 
All the values are expressed as mean ± S. D. (n = 3) 
 
Table 5: Post compression parameters 








¥ Drug Content Ӝ (%) 
F1 4.5±0.23 0.29±0.35 299.1± 1.74 3.41±0.4 99.35±0.32 
F2 4.0±0.37 0.34±0.71 300.1± 1.23 3.83±0.9 99.89±0.51 
F3 3.7±0.91 0.28±0.11 300.7± 1.89 3.87±0.2 98.76±0.96 
F4 4.4±0.73 0.55±0.03 299.3 ± 1.33 3.42±0.1 100.21±0.13 
F5  4.5±0.99 0.39±0.74 300.2± 1.98 3.64±0.7 99.43±0.73 
F6 3.9±0.93 0.45±0.81 299.8 ± 1.21 3.96±0.3 98.69±0.91 
F7 4.3±0.45 0.49±0.56 299.9± 1.45 3.55±0.9 100.31±0.17 
F8 4.8±0.14 0.53±0.87 300.7± 1.86 3.62±0.2 99.44±0.55 
F9 4.2±0.26 0.52±0.21 299.1± 1.14 3.58±0.3 100.38±0.18 
F10 4.7±0.27 0.47±0.35 300.4± 1.35 3.77±0.1 99.76±0.98 
All the values are expressed as mean ± S. D. ∗ n = 6, ∗∗n =10, ψn = 20, ¥ n = 6, Ӝ
 
 n = 2. 





% Cumulative drug release 
F1 F2 F3 F4 F5 
1 0 0 0 0 0 0 
2 1 3.06±0.31 5.4±0.53 3.96±0.98 8.28±0.32 2.88±0.86 
3 2 7.92±0.64 8.64±0.41 7.2±1.12 11.7±0.83 8.64±0.47 
4 3 11.52±0.25 12.06±0.46 14.4±0.64 13.86±0.45 16.02±0.57 
5 4 15.48±0.37 15.06±0.51 22.32±0.28 20.7±0.37 22.29±1.21 
6 5 24.6±0.41 19.7±0.76 26.85±0.47 22.74±1.12 25.74±0.96 
7 6 41.1±0.16 24.6±0.71 30.3±1.19 26.7±0.95 31.5±0.93 
8 7 55.5±0.29 36.3±0.54 33.9±1.24 29.4±0.84 39.3±1.69 
9 8 62.1±0.32 47.4±0.53 36.00±0.95 39.3±0.23 57.3±0.75 
10 9 66.3±0.19 60.3±0.42 45.3±0.86 54.9±1.78 63.00±0.69 
11 10 79.5±0.44 69.6±0.60 51.6±0.55 60.3±0.45 78.3±1.73 
12 11 84.3±0.46 87.0±0.61 60.00±0.73 75.00±1.31 84.00±0.83 
13 12 93.9±0.53 96.3±0.53 86.4±0.69 87.6±0.48 93.01±0.80 
The data are presented as mean value ± S. D. (n = 3) 
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% Cumulative drug release 
F6 F7 F8 F9 F10 
1 0 0 0 0 0 0 
2 1 3.24±0.39 7.2±0.83 10.44±0.59 5.4±0.99 6.84±0.91 
3 2 6.56±0.57 10.08±0.89 13.5±0.63 8.82±0.89 10.62±0.87 
4 3 14.88±0.29 14.74±0.81 15.84±1.45 15.66±0.75 16.2±0.77 
5 4 17.16±0.45 16.74±0.83 19.05±0.99 19.2±1.53 20.85±0.99 
6 5 26.22±1.31 20.19±0.73 22.29±0.94 25.95±0.64 26.79±0.85 
7 6 34.8±1.11 24.96±0.69 26.04±0.86 33.3±0.74 30±0.81 
8 7 39.00±0.92 41.1±0.77 42.9±0.84 41.1±1.18 39.6±0.62 
9 8 45.9±0.94 57.6±0.36 48.3±0.72 45±0.95 45.9±0.26 
10 9 58.5±0.84 61.8±0.89 51±0.88 54.9±0.91 58.8±0.35 
11 10 63.3±0.25 66.00±0.74 60±0.63 60.3±1.23 65.1±0.63 
12 11 81.6±0.87 69.3±0.63 66±0.86 69±0.93 66±0.72 
13 12 90.00±0.86 77.4±0.79 82.5±0.78 81±0.84 83.4±0.71 
The data are presented as mean value ± S. D. (n = 3) 
 


















F1 0.9748 0.8544 0.8428 0.9696 1.433 Super Case II 
transport 
F2 0.9345 0.6977 0.7651 0.9595 0.922 Non- fickian diffusion 
F3 0.9313 0.7078 0.8074 0.9826 1.174 Super Case II 
transport 
F4 0.9298 0.7656 0.7807 0.9727 0.676 Non- fickian diffusion 
F5 0.9716 0.8220 0.8313 0.9866 1.314 Super Case II 
transport 
F6 0.9700 0.8025 0.8271 0.9879 1.322 Super Case II 
transport 
F7 0.9558 0.9170 0.8293 0.9180 0.805 Non- fickian diffusion 
F8 0.9589 0.8419 0.8346 0.8586 0.628 Non- fickian diffusion 
F9 0.9874 0.8910 0.8671 0.9856 1.054 Case II transport 
F10 0.9778 0.8652 0.8573 0.9865 0.894 Non- fickian diffusion 
 
 




Fig. 11: Dissolution profiles of Formulations F4-F6 (Using HPMC 
K 4M & K 15M) 
 




Fig. 13: Dissolution profiles of Formulations F9, F10 (Using 
HPMC K 15M) 
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From the present study, the following conclusions can be drawn:  
 The purpose of the present study was to formulate and evaluate 
sustained release matrix tablets of Bosentan was prepared by wet 
granulation method by using different polymers of hydroxy propyl 
methyl cellulose grades.  
 Successfully using HPMC polymer of different viscosity. According 
to in vitro release studies, the release rate was decreased with 
increasing viscosity and amount of polymer. 
 IR spectra indicated the absence of probable chemical interaction 
between the drug and polymers used in different proportions. 
 DSC thermograms obtained for the pure drug and drug + different 
polymers indicated that there is no interaction for drug and polymers 
and suggested the good miscibility of the drug and polymers.  
 In-vitro dissolution studies showed that tablets of Bosentan in 
1:0.5 proportion, prepared by wet granulation is the best to increase 
sustain effect due to the polymer concentration.  
 All the formulations fulfill the official limit for Physicochemical 
parameters like weight variation, hardness, friability and drug 
content uniformity.  
 The optimized formulation of F2 gave the best in vitro release of 
96.3±0.53 in 12 hrs in simulated intestinal fluid. The release of drug 
followed matrix diffusion mechanism.  
 Hence it is concluded that among the Ten formulations of 
Bosentan, F-2 formulation containing Drug to polymer (HPMC K 4 
M) in ratio 1:0.5 is optimized based on its ability to sustain drug 
release till 12 hours in simulated intestinal fluid. The results of the 
study clearly demonstrated that HPMC matrix tablet formulation is 
an effective and promising drug delivery system for once a daily 
administration of Bosentan. 
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